JAK2 V617F mouse model validation testing provides researchers with rigorous genotyping, allele burden quantification, and phenotypic characterization to confirm the successful establishment and stability of myeloproliferative neoplasm (MPN) animal models. Our comprehensive validation platform combines allele-specific PCR, Sanger sequencing, quantitative real-time PCR, and droplet digital PCR (ddPCR) to deliver accurate, reproducible results for preclinical research and drug development programs.
Technical Overview
The JAK2 V617F mutation is a somatic gain-of-function point mutation (c.1849G>T) in the Janus kinase 2 (JAK2) gene, resulting in a valine-to-phenylalanine substitution at codon 617. This mutation is present in approximately 95% of patients with polycythemia vera (PV) and 50-60% of patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF), making it the most common molecular abnormality in Philadelphia chromosome-negative myeloproliferative neoplasms.
Mouse models carrying the human JAK2 V617F knock-in or transgene, including conditional knock-in models such as Jak2VF and humanized JAK2 V617F transgenic lines, spontaneously develop MPN-like phenotypes characterized by erythrocytosis, leukocytosis, splenomegaly, and bone marrow fibrosis. Rigorous validation testing is essential to confirm genotype status, quantify mutant allele burden, and verify that the observed hematological phenotype is consistent with the expected disease model. Our validation services cover every stage of model development, from founder line screening to longitudinal monitoring during preclinical studies.
Testing Samples
Genomic DNA Samples
High-quality genomic DNA extracted from tail snips, ear punches, or toe biopsies is the standard material for routine genotyping of JAK2 V617F mice. We recommend submitting 50-200 ng of DNA per reaction with an A260/A280 ratio between 1.8 and 2.0. Fresh tissue samples can also be submitted directly, and our laboratory will perform DNA extraction using validated protocols.
Peripheral Blood Samples
Peripheral blood collected from the tail vein, submandibular vein, or retro-orbital sinus in EDTA-coated tubes serves dual purposes: genotyping from buffy coat DNA and hematological phenotyping through complete blood count (CBC) analysis. A minimum volume of 50-100 μL is typically required, and samples should be processed within 24 hours of collection to preserve cell morphology and count accuracy.
Tissue Samples
Spleen, liver, and bone marrow samples are collected at necropsy for histopathological validation, allele burden quantification in hematopoietic organs, and molecular analysis. Spleen tissue is particularly informative because extramedullary hematopoiesis in JAK2 V617F mice leads to substantial splenic enlargement with high mutant allele frequencies. Tissues may be submitted fresh, snap-frozen, or fixed in formalin depending on the downstream assay requirements.
Sorted Cell Populations
Flow cytometry-sorted hematopoietic stem and progenitor cell (HSPC) populations, including LSK (Lineage-Sca-1+c-Kit+) cells, myeloid progenitors, and mature lineage subsets, can be submitted for lineage-specific allele burden analysis. This approach is critical for studies investigating the cell-of-origin of JAK2-driven myeloproliferative disease and for evaluating clonal dynamics under therapeutic pressure.
Testing Items
Our JAK2 V617F mouse model validation program encompasses the following core testing items:
- Genotype confirmation: identification of wild-type, heterozygous, and homozygous JAK2 V617F status at the targeted locus
- Mutant allele burden quantification: precise measurement of the V617F allele fraction in genomic DNA from blood, spleen, bone marrow, or sorted cells
- Zygosity determination for transgenic lines: copy number assessment of the human JAK2 V617F transgene integration
- Conditional knockout/knock-in verification: confirmation of Cre-mediated recombination efficiency in inducible models (e.g., Mx1-Cre, Vav-Cre, Scl-Cre-ERT2 systems)
- Hematological phenotyping: erythrocyte count, hemoglobin concentration, hematocrit, leukocyte differential, and platelet count
- Splenomegaly assessment: spleen weight, spleen-to-body-weight ratio, and histological evaluation of extramedullary hematopoiesis
- Bone marrow pathology: reticulin fibrosis grading, megakaryocyte hyperplasia, and cellularity assessment
- Longitudinal disease monitoring: serial allele burden tracking to evaluate disease progression or therapeutic response
Testing Methods
Allele-Specific PCR (AS-PCR)
Allele-specific PCR employs primers designed with a 3' nucleotide complementary to either the wild-type G allele or the mutant T allele, enabling rapid and cost-effective discrimination of genotypes. This method is well suited for high-throughput screening of breeding colonies and delivers results with high specificity when combined with optimized amplification conditions.
PCR-Restriction Fragment Length Polymorphism (PCR-RFLP)
The JAK2 V617F mutation abolishes an XbaI restriction site present in the wild-type sequence. Following PCR amplification of the target region, XbaI digestion generates distinguishable fragment patterns for wild-type, mutant, and heterozygous samples. PCR-RFLP remains a robust and economical genotyping approach that requires no specialized equipment beyond standard gel electrophoresis.
Sanger Sequencing
Direct sequencing of PCR amplicons spanning exon 14 (or exon 12 in murine Jak2 numbering) provides definitive confirmation of the V617F mutation and reveals any additional sequence variants. Sanger sequencing reliably detects mutant allele fractions down to approximately 15-20%, making it ideal for founder line confirmation and verification of gene-edited alleles, while serving as an orthogonal validation method for results obtained by other platforms.
Quantitative Real-Time PCR (qPCR)
TaqMan-based allele discrimination assays use dual-labeled hydrolysis probes specific for the wild-type and mutant alleles, enabling both qualitative genotyping and quantitative allele burden measurement. qPCR assays achieve analytical sensitivity of approximately 1% mutant allele fraction and support high-throughput processing of longitudinal sample sets from preclinical efficacy studies.
Droplet Digital PCR (ddPCR)
Droplet digital PCR partitions reactions into thousands of individual droplets, enabling absolute quantification of mutant and wild-type allele copies without the need for standard curves. ddPCR provides the highest analytical sensitivity in our portfolio, detecting mutant allele fractions as low as 0.1-0.5%, which is essential for minimal residual disease assessment, monitoring of partial therapeutic responses, and early detection of clonal expansion in competitive chimerism experiments.
Complete Blood Count and Flow Cytometry
Automated hematology analyzers validated for murine samples generate comprehensive CBC data, confirming characteristic MPN phenotypes such as elevated hematocrit and red cell mass in PV-like models. Flow cytometric immunophenotyping quantifies mature and immature hematopoietic subsets in blood, spleen, and bone marrow, providing high-resolution phenotypic validation of the disease state.
Applications
JAK2 V617F mouse model validation testing supports a wide range of research and development applications:
- Preclinical drug efficacy evaluation for JAK inhibitors such as ruxolitinib, fedratinib, and pacritinib, using allele burden reduction as a pharmacodynamic biomarker
- Pathogenesis research into myeloproliferative neoplasm development, clonal evolution, and progression to myelofibrosis or acute myeloid leukemia
- Hematopoietic stem cell biology studies examining the cell-intrinsic and microenvironmental effects of constitutive JAK-STAT signaling
- Gene therapy and targeted degradation approaches, including PROTAC and allele-specific silencing strategies
- Immune and inflammation research, given the established role of JAK signaling in cytokine-mediated inflammatory pathways
- Colony management for breeding programs, ensuring correct genotyping of experimental cohorts and maintenance of conditional alleles
- Biomarker discovery and validation, correlating mutant allele dynamics with hematological and histopathological endpoints
- Translational bridging studies that connect murine model findings to clinical observations in human MPN patients
FAQ
What is the JAK2 V617F mutation and why is it important in mouse models?
JAK2 V617F is a constitutively activating mutation in the pseudokinase domain of JAK2 that drives uncontrolled signaling through the JAK-STAT pathway. Mice carrying this mutation faithfully recapitulate human myeloproliferative neoplasms, making validated JAK2 V617F models indispensable tools for studying MPN biology and evaluating new therapies.
What sample types are accepted for genotyping?
We accept tail snips, ear punches, EDTA whole blood, buffy coat DNA, sorted cell pellets, and extracted genomic DNA. For allele burden analysis in disease monitoring, peripheral blood and spleen-derived DNA are the most commonly submitted sample types.
Which detection method should I choose for my study?
PCR-RFLP and allele-specific PCR are recommended for routine colony genotyping. Sanger sequencing is suitable for founder confirmation and mutation verification. qPCR offers quantitative allele burden measurement with approximately 1% sensitivity, while ddPCR is the preferred choice when ultra-sensitive detection below 0.5% is required, such as in minimal residual disease monitoring.
What is mutant allele burden and why does it matter?
Mutant allele burden refers to the proportion of JAK2 V617F alleles relative to total JAK2 alleles in a sample. It correlates with disease severity in both patients and mouse models, serves as a key pharmacodynamic biomarker for JAK inhibitor studies, and provides a quantitative metric for tracking clonal dynamics over time.
How long does validation testing take?
Standard genotyping by PCR-RFLP or AS-PCR is typically completed within 3-5 business days. Sequencing-based confirmation requires 7-10 business days, and ddPCR quantification is generally reported within 7 business days, depending on sample volume and project scope.
Can longitudinal monitoring be performed on individual mice?
Yes, serial blood sampling allows repeated allele burden measurement in the same animals over time. This study design reduces animal numbers, controls for inter-individual variability, and enables precise tracking of disease progression or therapeutic response within individual subjects.
How is the phenotype confirmed in addition to the genotype?
Phenotypic validation combines complete blood count analysis (elevated hematocrit, hemoglobin, and white cell counts), spleen weight measurement with spleen-to-body-weight ratio calculation, and histopathological examination of spleen, liver, and bone marrow for extramedullary hematopoiesis and reticulin fibrosis. Concordance between genotype and phenotype confirms proper model establishment.